Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

1999 • 2,565 citations

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

2010 • 2,394 citations

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

2006 • 1,280 citations

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

2012 • 1,107 citations

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

2012 • 1,098 citations

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

2008 • 884 citations

Efficacy of Lenalidomide in Myelodysplastic Syndromes

2005 • 857 citations

The evolution of thalidomide and its IMiD derivatives as anticancer agents

2004 • 774 citations

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

1999 • 726 citations

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

2012 • 724 citations

Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α

1999 • 618 citations

CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling

2001 • 555 citations

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

2011 • 473 citations

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

2011 • 455 citations

Mechanism of action of lenalidomide in hematological malignancies

2009 • 430 citations

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

2007 • 424 citations

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes

2001 • 311 citations

Narrowing and genomic annotation of the commonly deleted region of the 5q− syndrome

2002 • 259 citations

Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission

2010 • 246 citations

Lenalidomide inhibits the malignant clone and up-regulates theSPARCgene mapping to the commonly deleted region in 5q− syndrome patients

2007 • 231 citations

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

2003 • 206 citations

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

2009 • 188 citations

Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells

2008 • 174 citations

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

2008 • 167 citations

CD45, CD148, and Lyp/Pep: critical phosphatases regulating Src family kinase signaling networks in immune cells

2009 • 161 citations

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

2008 • 151 citations

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study

2012 • 119 citations

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

2010 • 116 citations

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

2010 • 110 citations

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

2008 • 108 citations

Functional cdc25C Dual-Specificity Phosphatase Is Required for S-Phase Entry in Human Cells

2003 • 83 citations

Many Fingers on the Mitotic Trigger: Post-Translational Regulation of the Cdc25C Phosphatase

2004 • 73 citations

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

2011 • 72 citations

Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

2005 • 63 citations

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion

2009 • 48 citations

The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities

2009 • 44 citations

CC-5013 (Celgene).

2004 • 42 citations

The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes

2007 • 41 citations

Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed

2010 • 32 citations

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses

2006 • 32 citations

Changes in RPS14 expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion

2010 • 30 citations

Role of Lenalidomide in the Treatment of Myelodysplastic Syndromes

2011 • 21 citations

Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease.

2005 • 20 citations

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)

2010 • 17 citations

Two-Stage Pharmacokinetic & Efficacy Study of Lenalidomide Alone or Combined with Recombinant Erythropoietin (EPO) in Lower Risk MDS EPO-Failures [PK-002].

2007 • 10 citations

Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.

2011 • 7 citations

Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study

2011 • 6 citations

Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

2011 • 6 citations

5q- Myelodysplastic Syndrome, In One of 23 Children Lacking a Known Ribosomal Gene Mutation, Masquerading as Diamond Blackfan Anemia (DBA) and Responding to Lenalidomide

2010 • 6 citations

A Simulation Study Using Validated Prognostic Factors to Assess Expected Long-term Survival

2005 • 4 citations

Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases

2011 • 4 citations

Lenalidomide Upregulates Erythropoietin Receptor Expression in Hematopoietic Progenitors by Modulating Receptor Turnover

2011 • 4 citations

Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes

2011 • 4 citations

5q- Syndrome In a Child: Is This Acquired Diamond Blackfan Anemia (DBA)?

2010 • 1 citations

Deleted Work

1955 • 0 citations